Stocktoria
Vaxart, Inc. VXRT
Vaxart, Inc. (VXRT) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $237.3M at a 6.9% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.265 |
| Retained earnings / assets | -2.473 |
| EBIT / assets | 0.097 |
| Equity / liabilities | 0.893 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| VXRT | Vaxart, Inc. | 5/9 | -4.73 | 8.3 | +726.7% |
| IOVA | IOVANCE BIOTHERAPEUTICS, INC. | 2/9 | -7.27 | — | +60.6% |
| VCEL | Vericel Corp | 7/9 | 3.1 | 118.9 | +16.5% |
| ADAPY | Adaptimmune Therapeutics PLC | 3/9 | -13.03 | — | +195.3% |
| RGNX | REGENXBIO Inc. | 3/9 | -7.82 | — | +104.5% |
| GLUE | Monte Rosa Therapeutics, Inc. | 4/9 | 1.67 | — | +63.5% |
| ATRA | Atara Biotherapeutics, Inc. | 4/9 | — | 2.9 | -6.3% |
About Vaxart, Inc.
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII; COVID-19 Vaccine, which is in Phase 2b clinical trial for the treatment of SARS-CoV-1, SARS-CoV-2, and Middle East respiratory syndrome coronavirus; Seasonal Influenza vaccine, which is in Phase 2 clinical trial, to treat H1N1 Influenza; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. The company also provides VAAST (Vector-Adjuvant-Antigen Standardized Technology) Platform, a unique modular vaccine platform. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
FAQ
Is VXRT financially healthy?
Vaxart, Inc.'s Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does VXRT pay a dividend?
No, Vaxart, Inc. does not currently pay a dividend.
How profitable is VXRT?
In FY2025, Vaxart, Inc. had a net margin of 6.9% and a return on equity of 18.6%.
What is VXRT's P/E ratio?
Vaxart, Inc.'s trailing price-to-earnings (P/E) ratio is about 8.3×, based on its latest annual earnings.
What is the analyst price target for VXRT?
The average Wall-Street price target for Vaxart, Inc. is $3.00, about 435.7% above the recent price, from 2 analysts.
Is VXRT a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Vaxart, Inc.: a Piotroski F-score of 5/9, an Altman Z″ in the distress zone, a P/E of about 8.3×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.